Johnf Paolini News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Johnf paolini. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Johnf Paolini Today - Breaking & Trending Today

Kiniksa Pharmaceuticals (KNSA) Announces Development Indication for Abiprubart

Kiniksa Pharmaceuticals (KNSA) Announces Development Indication for Abiprubart
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Johnf Paolini , Sanjk Patel , Kiniksa Pharmaceuticals Ltd , Kiniksa Pharmaceuticals , Chief Executive Officer , Clinical Trial , Syndrome Disease Activity Index , Least Squares , Disease Activity Score , Usingc Reactive Protein , Rheumatoid Factor , Chief Medical Officer ,

Wedbush Weighs in on Kiniksa Pharmaceuticals, Ltd.'s Q1 2025 Earnings (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Wednesday, February 28th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.17) per share for the quarter. Wedbush […] ....

Johnf Paolini , Mark Ragosa , Kiniksa Pharmaceuticals Ltd , Kiniksa Pharmaceuticals Company Profile , News Ratings For Kiniksa Pharmaceuticals Daily , Altshuler Shaham Ltd , Kiniksa Pharmaceuticals Price Performance , China Universal Asset Management Co , Kiniksa Pharmaceuticals , Securities Exchange Commission , Royal Bank , Advisors Inc , Lazard Asset Management , Free Report , Kiniksa Pharmaceutical , Asset Management , Shaham Ltd , China Universal Asset Management , Universal Asset Management , Exchange Commission , Get Free Report , Kiniksa Pharmaceuticals Daily , Nasdaq Knsa , Earnings Estimates ,

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 1-Year High at $20.94

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $20.94 and last traded at $20.83, with a volume of 197612 shares traded. The stock had previously closed at $20.16. Analyst Ratings Changes KNSA has been the topic of […] ....

Johnf Paolini , Michaelr Megna , Tower Research Capital , Altshuler Shaham Ltd , News Ratings For Kiniksa Pharmaceuticals Daily , Lazard Asset Management , Kiniksa Pharmaceuticals Stock Performance , Kiniksa Pharmaceuticals Ltd , Royal Bank , Securities Exchange Commission , Advisors Inc , Kiniksa Pharmaceuticals , Get Free Report , Exchange Commission , Research Capital , Asset Management , Shaham Ltd , Kiniksa Pharmaceuticals Daily , Nasdaq Knsa ,

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High at $20.94

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $20.94 and last traded at $20.83, with a volume of 197612 shares traded. The stock had previously closed at $20.16. Analyst Upgrades and Downgrades A number of research analysts […] ....

Johnf Paolini , Michaelr Megna , News Ratings For Kiniksa Pharmaceuticals Daily , Institutional Trading Of Kiniksa Pharmaceuticals , Kiniksa Pharmaceuticals Ltd , Securities Exchange Commission , Insider Transactions At Kiniksa Pharmaceuticals , Kiniksa Pharmaceuticals , Morgan Stanley , Blackrock Inc , Vanguard Group Inc , Kiniksa Pharmaceuticals Price Performance , Get Free Report , Exchange Commission , Capital Management , Street Corp , Kiniksa Pharmaceuticals Daily , Nasdaq Knsa ,

Q1 2025 Earnings Estimate for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Issued By Wedbush

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) – Stock analysts at Wedbush issued their Q1 2025 EPS estimates for Kiniksa Pharmaceuticals in a research report issued on Wednesday, February 28th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.17) for the quarter. Wedbush currently has a “Outperform” rating and […] ....

Johnf Paolini , Michaelr Megna , Kiniksa Pharmaceuticals Stock Down , Securities Exchange Commission , Kiniksa Pharmaceuticals , Blackrock Inc , Vanguard Group Inc , News Ratings For Kiniksa Pharmaceuticals Daily , Kiniksa Pharmaceuticals Ltd , Morgan Stanley , Free Report , Kiniksa Pharmaceutical , Pharmaceuticals Stock Down , Capital Management , Street Corp , Exchange Commission , Get Free Report , Kiniksa Pharmaceuticals Daily , Nasdaq Knsa , Earnings Estimates ,